Biological molecules are increasingly becoming a part of the therapeutics portfolio that has
been either recently approved for marketing or those that are in the pipeline of several …

Management of RA patients has significantly improved over the past decades. However, a
substantial proportion of patients is difficult-to-treat (D2T), remaining symptomatic after …

In oncology, an increasing number of targeted anticancer agents and immunotherapies are
of biological origin. These biological drugs may trigger immune responses that lead to the …

The generation of antibodies following exposure to therapeutic drugs has been widely
studied, however in oncology, data in relation to their clinical relevance are limited. Antidrug …

Introduction: Checkpoint inhibitors, including the CTLA-4 blocking antibody ipilimumab,
have become the new standard therapy for many metastatic cancers. Development of anti …

Objectives To evaluate the safety and maintenance of efficacy with ABT-122, a bi-specific
monoclonal antibody targeting TNF and IL-17A, in patients with RA or PsA in open-label, 24 …

Many BAs have become available as new therapeutic tools, including monoclonal antibody
(mAb), cytokines, and fusion proteins. Since their approval, BA therapy had a positive impact …

The ability of biotherapeutics to induce immune response in patients has been broadly
accepted. Humoral immune response to biotherapeutics is expected to be polyclonal in …

Background Vilobelimab, a complement 5a (C5a)-specific monoclonal antibody, reduced
mortality in critically ill COVID-19 patients in a phase 3 multicentre, randomized, double …

There is ample growth potential in the current biologics era. There are more than 1,600
biologics under evaluation where over 250 approved drugs and many more drugs are in the …